Isolation and characterization of the B-cell marker CD20

Area of Science:

• Biochemistry
• Immunology
• Oncology

Background:

• CD20 is a key therapeutic target for non-Hodgkin's lymphoma (NHL).
• Antibody binding to CD20, like rituximab, is conformation-dependent, particularly on a loop between transmembrane regions.
• Understanding CD20 structure and antibody interaction is crucial for optimizing NHL therapies.

Purpose of the Study:

• To characterize the structural properties of purified human and murine CD20.
• To investigate the role of disulfide bonds in rituximab binding to CD20.
• To explore the influence of B cell membrane presentation on rituximab-CD20 interactions.

Main Methods:

• Expression and purification of human and murine CD20 in E. coli.
• Circular dichroism spectroscopy to assess protein secondary structure.
• Binding assays using rituximab and its Fab fragment with purified CD20 and B cells.
• Site-directed mutagenesis to investigate cysteine residue roles.

Main Results:

• Purified CD20 exhibits significant helical structure, largely unaffected by reduction, SDS, or heat.
• Rituximab binds purified CD20 with nanomolar affinity, dependent on a disulfide bond between Cys167 and Cys183.
• Rituximab Fab and intact antibody show similar affinity to purified CD20, but intact antibody exhibits higher avidity on B cells.
• B cell CD20 presentation likely involves lipid raft cross-linking, enhancing avidity and therapeutic efficacy.

Conclusions:

• The disulfide-bonded loop (Cys167-Cys183) is critical for rituximab epitope recognition.
• B cell surface organization of CD20 significantly enhances rituximab binding avidity, likely via lipid rafts.
• These findings provide insights into the mechanism of action for anti-CD20 antibody therapies in NHL.